Skip to main content
Canada approves Celgene's Pomalyst-based regimen for multiple myeloma

Celgene's triplet therapy of Pomalyst, or pomalidomide, Takeda's Velcade, or bortezomib, and dexamethasone, a treatment indicated for multiple myeloma patients who have undergone at least a single treatment containing Revlimid, or lenalidomide, has received the approval of Health Canada.

Full Story: